Oligonucleotide Separations with RP Phases

HPLC, UHPLC

Oligonucleotide Separations with RP Phases

04 Feb, 2019

Published over 7 years ago. See the latest and most current information on HPLC, UHPLC.

Therapeutic oligos represent an important area of research in the pharmaceutical industry today. These drug candidates are typically 8-50 nucleotides long and contain single-stranded DNA or RNA. Oligonucleotides are typically analysed using ion-pairing chromatography. Oligonucleotides are easily degraded via phosphodiester-cleaving enzymes. However, with a thiophosphate modified phosphate group, the stability significantly increases. Phosphorothioate modified oligos will have a stereocenter at each modified phosphate group, leading to 2n-1 diastereomers, all with an individual retention time in the chromatography. For a 20-nucleotide long oligo, that’s 524 288 species present. The partial resolution of these species results in peak broadening, further complicating chromatographic separation. To resolve the problem, ion-pairing agents with longer alkyl chains can be used.

In a study of the influence of stationary phase and ion-pairing agent on the separation of oligos, Kromasil Phenyl showed to be a very good choice when separating oligonucleotides in general, exhibiting very sharp peaks, and good selectivity.

View these applications on www.kromasil.com/oligos.

Explore Our Other Sites

Labmate Online
Novel CAR T cell therapy shows strong early promise to 'eliminate' glioblastoma
Explore more Arrow
Envirotech Online
EU ETS benchmark update puts industrial emissions data under sharper scrutiny
Explore more Arrow
Pollution Solutions Online
Next-generation reverse osmosis membranes for more efficient and cost-effective seawater desalination
Explore more Arrow
Petro Online
New test method ASTM D8606 has been officially released
Explore more Arrow